ALKS Alkermes plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS

Price (delayed)

$43.54

Market cap

$7.26B

P/E Ratio

46.82

Dividend/share

N/A

EPS

$0.93

Enterprise value

$8.49B

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 66

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
Alkermes's gross profit has increased by 6% YoY and by 6% from the previous quarter
The revenue has grown by 6% from the previous quarter and by 3.2% YoY
The company's equity rose by 16% YoY but it fell by 3.7% QoQ
ALKS's P/E is 117% above its last 4 quarters average of 21.2
Alkermes's net income has plunged by 57% YoY and by 37% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Peers: JNJ BMY NVS TEVA

Key stats

What are the main financial stats of ALKS

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
1.82%
1 week
9.01%
1 month
27.42%
1 year
38.05%
YTD
55.61%
QTD
23.13%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$1.35B
Operating income
$191.88M
Net income
$152.72M
Gross margin
86.6%
Net margin
9.8%
The net margin has plunged by 58% YoY and by 40% from the previous quarter
Alkermes's net income has plunged by 57% YoY and by 37% from the previous quarter
The company's operating margin has shrunk by 52% YoY and by 28% QoQ
Alkermes's operating income has plunged by 51% YoY and by 24% from the previous quarter

Price vs fundamentals

How does ALKS's price correlate with its fundamentals

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
ALKS P/E details
P/E
46.82
P/B
4.14
P/S
4.63
EV/EBIT
35.78
EV/EBITDA
30.71
EV/Sales
5.43
ALKS's P/E is 117% above its last 4 quarters average of 21.2
The EPS has dropped by 57% year-on-year and by 37% since the previous quarter
The P/B is 40% higher than the last 4 quarters average of 2.9 and 13% higher than the 5-year quarterly average of 3.6
The company's equity rose by 16% YoY but it fell by 3.7% QoQ
ALKS's P/S is 38% above its last 4 quarters average of 3.3 and 34% above its 5-year quarterly average of 3.4
The revenue has grown by 6% from the previous quarter and by 3.2% YoY

Efficiency

How efficient is Alkermes business performance
The ROA has shrunk by 67% YoY and by 49% QoQ
The return on equity has dropped by 65% year-on-year and by 39% since the previous quarter
The ROS has declined by 47% year-on-year and by 26% since the previous quarter
The ROIC has decreased by 47% YoY and by 39% from the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 70% higher than its total liabilities
Alkermes's total assets has surged by 105% YoY and by 71% QoQ
ALKS's quick ratio is down by 50% since the previous quarter and by 44% year-on-year
The debt is 10% less than the equity
The company's equity rose by 16% YoY but it fell by 3.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.